Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area metabolism pde'

Search results for: 'research area metabolism pde'

Items 91-100 of 100

Page
per page
  1. Milrinone
    B1386 Milrinone
    Target: Phosphodiesterases (PDEs)
    Summary: PDE-3 inhibitor
      insoluble in H2O; insoluble in EtOH; ≥8.2 mg/mL
  2. (±)-Decanoylcarnitine chloride
    B6315 (±)-Decanoylcarnitine chloride
    Summary: intermediate in lipid metabolism
      <35.19 mg/mL
  3. (±)-Acetylcarnitine chloride
    B6273 (±)-Acetylcarnitine chloride
    Summary: weak cholinergic agonist; intermediates in lipid metabolism
      <23.97 mg/mL
  4. (±)-Myristoylcarnitine chloride
    B6354 (±)-Myristoylcarnitine chloride
    Summary: cholinergic agonist; important intermediates in lipid metabolism
      <10.2 mg/mL
  5. Malotilate
    A2486 Malotilate
    Summary: Stimulates hepatocyte regeneration
      insoluble in H2O; ≥14.419 mg/mL
  6. Zardaverine
    A3950 Zardaverine
    Summary: PDE III and IV inhibitor
      Soluble in DMSO
  7. MBCQ
    C3510 MBCQ
    Summary: cGMP-specific phosphodiesterase PDE V inhibitor
      Soluble in DMSO
  8. Adenosine-5'-diphosphate
    C4341 Adenosine-5'-diphosphate
    Summary: central component of energy storage, metabolism, and signal transduction in vivo;agonist of purinergic receptors
      ≥21.35 mg/mL
  9. Etazolate hydrochloride
    B6304 Etazolate hydrochloride
     2 Citation
    Target: Phosphodiesterases (PDEs)
    Summary: PDE-4 inhibitor and selective GABA-A receptor modulator
      ≥7.75 mg/mL
  10. BMS 309403
    B7794 BMS 309403
     2 Citation
    Target: Fatty-acid-binding proteins (FABPs)
    Summary: FABP4 inhibitor,potent and selective
      insoluble in H2O; ≥18.15 mg/mL

Items 91-100 of 100

Page
per page
Shop By
Now Shopping by
  1. Category Metabolism Remove This Item
Clear All
Shopping Options
Category
  1. PPAR 11item
  2. 5-Lipoxygenase 1 item
  3. Carbonic Anhydrase 6item
  4. CETP 4item
  5. CYP3A/CYP450 3item
  6. Dehydrogenase 7item
  7. DHFR 3item
  8. DGAT 3item
  9. Dopamine β-hydroxylase 3item
  10. FAAH 3item
  11. Factor Xa 2item
  12. Ferroptosis 1 item
  13. Folate Analogue 1 item
  14. HLE 1 item
  15. HMG-CoA Reductase 4item
  16. IDO 1 item
  17. Lipid Metabolism 4item
  18. MAO 3item
  19. P450 6item
  20. PDE 21item
  21. Phospholipase 1 item
  22. Procollagen C Proteinase 1 item
  23. SCD 1 item
  24. SGLT 2item
  25. Transferase 6item
  26. Others 1 item
Specificity
  1. Selective 44item
  2. Non-Selective 1 item
Reversibility
  1. Reversible 1 item
  2. Irreversible 4item
Target
  1. Acyl coenzyme A: cholesterol acyltransferases 1 item
  2. Factor Xa 1 item
  3. Phosphodiesterases (PDEs) 13item
  4. RARs 1 item
  5. Stearoyl-CoA 9-desaturase (SCD-1) 1 item
  6. Cytochrome P450 (CYP450) 4item
  7. Ferroptosis 1 item
  8. HMG-CoA Reductases 3item
  9. SGLT 1 item
  10. DGAT 2item
  11. Insulin and Insulin-like Receptors 1 item
  12. Pyruvate dehydrogenases (PDH) 1 item
  13. CETP 2item
  14. Fatty-acid-binding proteins (FABPs) 1 item
  15. Folate Analogue 1 item
  16. IDH2 1 item
  17. Nampt 1 item
  18. Carbonic Anhydrases 3item
  19. Phospholipases 1 item
  20. Catechol O-Methyltransferase (COMT) 1 item
  21. Hydroxylases 1 item
  22. FPTase 1 item
  23. PPAR 1 item
  24. FAAH 1 item
  25. carnitine reabsorption 1 item
Reported Experiments
  1. Animal Experiments 54item
  2. Cell Experiments 42item
Related Disease
  1. Acne 1 item
  2. Acute Kidney Injury 1 item
  3. Acute Myelogenous Leukemia 1 item
  4. Bladder Cancer 1 item
  5. Bladder Carcinoma 1 item
  6. Brain Injuries Studies 1 item
  7. Breast Cancer 5item
  8. Cancer 13item
  9. Cervical Cancer 1 item
  10. Cocaine-Related Disorders 1 item
  11. Diabetes 1 item
  12. Dyslipidemia 1 item
  13. Erectile Dysfunction 3item
  14. Hypercholesterolemia 2item
  15. Inflammation 1 item
  16. Inflammatory Diseases 2item
  17. Kidney Injury Studies 1 item
  18. Leukemia 2item
  19. Lung Cancer 2item
  20. Lymphoma 3item
  21. Melanoma 2item
  22. Neuroblastoma 3item
  23. Neurocognitive Disorders 1 item
  24. Obsessive-Compulsive Disorder 1 item
  25. Prostate Cancer 2item
  26. Psoriasis 2item
  27. Psoriasis Vulgaris 1 item
  28. Pulmonary Arterial Hypertension 1 item
  29. Rheumatoid Arthritis 2item
  30. Schizophrenia 2item
  31. Type 2 Diabetes 4item